Necrotizing enterocolitis (NEC) is a life-threatening intestinal disease that affects premature infants, and certain baby formulas—particularly cow’s milk-based formulas without human milk oligosaccharides (HMOs)—have been linked to increased risk of this condition in vulnerable infants. Federal litigation is ongoing against formula manufacturers over allegations that they failed to warn parents and healthcare providers about this risk or market formulas that posed unnecessary danger to preterm infants. Families whose infants developed NEC after consuming certain formulas may be eligible for compensation through mass tort litigation, settlements, or individual lawsuits.
NEC occurs when the intestinal tissue of a newborn becomes inflamed and begins to die, potentially leading to sepsis, multi-organ failure, and death. For infants born before 37 weeks of gestation, the risk of NEC is significantly higher than for full-term infants, and the disease progresses rapidly—sometimes within days of symptom onset. Parents of affected infants have pursued legal action based on the theory that formula manufacturers knew or should have known that certain feeding practices and formulation choices increased NEC risk but failed to adequately communicate this to consumers or medical professionals.
Table of Contents
- What Is NEC and Why Are Premature Infants at Higher Risk?
- The Medical Evidence Linking Formula Composition to NEC Risk
- Which Formulas and Manufacturers Are Subject to Litigation?
- Who Qualifies to File an NEC Baby Formula Lawsuit?
- Settlement Amounts and Compensation in NEC Cases
- The Process of Filing an NEC Claim and Required Documentation
- The Future Outlook for NEC Formula Litigation and Prevention
What Is NEC and Why Are Premature Infants at Higher Risk?
Necrotizing enterocolitis is an infection and inflammation of the intestines in newborns that can cause tissue death and perforation of the bowel. The disease is most common in preterm infants (born before 37 weeks) and extremely low birth weight infants (under 1,000 grams), but it can affect any newborn. The exact cause of NEC is not fully understood, though risk factors include prematurity, rapid feeding advancement, formula feeding (as opposed to human breast milk), and bacterial colonization of the intestines. When a preterm infant’s intestinal barrier is not fully developed—which occurs in the third trimester—pathogenic bacteria can breach the intestinal lining and trigger a severe inflammatory response.
Premature infants lack the gut maturity and immune system development of full-term newborns. Their intestinal lining is more permeable, their protective mucus layer is thinner, and their immune response is underdeveloped. medical research has consistently shown that human breast milk provides protective factors—including antibodies, proteins like lactoferrin, and human milk oligosaccharides—that reduce NEC incidence compared to formula-fed infants. Studies comparing feeding methods show that exclusively breastfed preterm infants have NEC rates around 2-3 percent, while formula-fed preterm infants experience rates as high as 7-10 percent depending on formula type. The difference is significant enough that neonatal intensive care units (NICUs) prioritize breast milk feeding and have created donor milk banks specifically because of NEC prevention benefits.
The Medical Evidence Linking Formula Composition to NEC Risk
The litigation centers on claims that certain formula types—particularly cow’s milk formulas lacking human milk oligosaccharides (HMOs) and other immune-protective compounds—carry higher NEC risk than formulas with these components. HMOs are indigestible carbohydrates found exclusively in human breast milk that promote the growth of beneficial bacteria and strengthen intestinal barrier function. For decades, formula manufacturers did not include HMOs in their products, though the scientific basis for their protective effect was published in peer-reviewed journals throughout the 2000s and 2010s. Only in recent years have major manufacturers begun adding HMOs to infant formulas marketed for preterm infants.
A significant limitation of the current litigation is that while the scientific literature supports the protective benefits of HMOs and the higher risk profile of standard cow’s milk formulas, proving direct causation between a specific formula brand and an individual infant’s NEC diagnosis is medically complex. NEC is multifactorial—prematurity degree, birth weight, feeding protocols at the hospital, bacterial exposure, and other factors all contribute. Additionally, many infants received multiple formulas during their NICU stay as parents switched products or hospitals changed supplies. Some families pursued claims only to find that establishing causation required expert testimony and medical records that might be unavailable if the infant was treated at multiple facilities years earlier.
Which Formulas and Manufacturers Are Subject to Litigation?
The primary focus of NEC litigation has been on major manufacturers including Abbott Laboratories (Similac), Nestlé (Gerber Good Start), and Mead johnson (Enfamil), though the most significant litigation has centered on Similac products, particularly Similac Expert Care Neocare, which was specifically marketed for premature infants. These formulas did not contain HMOs and were cow’s milk-based. Between 2010 and 2020, thousands of families reported that their premature infants developed NEC after consuming these formulas, with some cases resulting in death or permanent disability including intestinal strictures, short bowel syndrome, or developmental delays from sepsis. The timeline of claims is important because it reflects when parents and medical professionals became aware of potential risks.
Initial lawsuits began filing around 2016-2017 as medical literature increasingly highlighted HMO benefits and the gap between formula offerings and breast milk composition became more apparent. By 2020-2021, several multidistrict litigations (MDLs) consolidated claims across federal courts. As of 2024-2025, some settlements have been reached while others remain in litigation, with claim filing deadlines varying by specific case and jurisdiction. It’s critical for families to understand that different litigation tracks have different deadlines—missing a deadline can bar recovery entirely.
Who Qualifies to File an NEC Baby Formula Lawsuit?
To qualify for NEC formula litigation, an infant must have been diagnosed with necrotizing enterocolitis and been fed a named formula product (typically a Similac product in major current cases) during the NICU period. The infant must have been born prematurely—most claims involve infants born before 37 weeks of gestation. Additionally, the family must typically have medical records documenting the NEC diagnosis, the formula used, and the timeline of feeding. Some cases have specific inclusion criteria around the degree of prematurity or severity of NEC, with more severe cases (those resulting in death or requiring surgery) often receiving higher compensation consideration.
However, there are important limitations. If an infant was only briefly exposed to the suspect formula, or if the formula was not the primary feed for the infant, the claim strength may be weaker. Insurance coverage and statute of limitations are also critical: claims must usually be filed within a certain window from the infant’s birth or diagnosis, and some states have different rules about tolling (pausing) the statute of limitations for minors. For families whose infants were born many years ago, they may have missed critical deadlines without knowing litigation was available. One tradeoff families should understand is that pursuing litigation requires providing extensive medical records and sometimes participating in depositions, which can be emotionally difficult when the case involves an infant who died or suffered severe complications.
Settlement Amounts and Compensation in NEC Cases
Settlement amounts in NEC litigation vary dramatically based on case severity. Infants who died from NEC have resulted in settlements and verdicts ranging from $500,000 to over $10 million, depending on state law, jurisdiction, and negotiated terms. Infants who survived NEC but required surgical intervention (bowel resection, colostomy) or suffered complications like short bowel syndrome have received settlements typically in the $300,000 to $2 million range. Cases involving less severe NEC presentations—infants who recovered with medical management only—may receive $50,000 to $300,000 depending on ongoing medical needs. One important warning is that advertised settlement ranges are often highest-case scenarios and reflect the most severe injuries.
The median recovery is typically lower than maximum reported amounts. Additionally, many settlements include structured payments paid out over time rather than lump sums, and they often exclude certain costs like past medical expenses already covered by insurance. Legal fees, typically 25-33 percent of recovery, are deducted before families receive their share. Some settlements also include payments toward future medical care in trusts, which may be inaccessible for immediate family needs. Families should request detailed settlement breakdowns before accepting—what appears to be a $1 million settlement might result in $400,000-500,000 in net family compensation after legal fees and medical setoffs.
The Process of Filing an NEC Claim and Required Documentation
Filing an NEC formula claim typically begins by contacting an attorney specializing in mass tort litigation or product liability. The initial step involves gathering medical records from the hospital where the infant was treated—NICU discharge summaries, feeding logs, NEC diagnosis documentation, and pathology reports if surgery was performed. Families will need to provide the specific formula products used, including dates of consumption if possible. For cases handled through MDLs, the law firm will file a complaint in the appropriate federal court containing the infant’s information, timeline, and damages claim.
For settlement program claims, families submit a claim form with documentation to a claims administrator. A practical comparison: filing through an MDL litigation process can take 2-5 years or longer and requires ongoing attorney communication and potential deposition participation, but it allows for higher recovery potential if the case goes to trial or a favorable settlement. Settling through an already-established settlement program or claims fund may result in faster resolution (6-18 months) but typically with lower individual payouts. Families must weigh the tradeoff between faster closure and potentially lower compensation versus extended litigation with higher but uncertain recovery.
The Future Outlook for NEC Formula Litigation and Prevention
As formula manufacturers have begun adding HMOs and other human milk components to their products—particularly in formulas marketed for preterm infants—the landscape of NEC litigation may shift. Newer product formulations marketed since 2020 may face less litigation exposure if they include HMO additions, though manufacturers’ marketing and knowledge of risks during earlier years remains central to existing claims. Ongoing research continues to clarify the relationship between specific formula components and NEC risk, which could strengthen or weaken future litigation arguments.
Preventatively, NICU practices have increasingly emphasized human milk feeding and use of donor milk when maternal milk is unavailable, significantly reducing NEC incidence in some healthcare systems. However, disparities remain—families with less access to lactation support or donor milk may still rely on standard formulas, perpetuating the risk differential. For families considering the future, understanding that NEC remains a real but preventable risk with modern best practices and advanced formulas can inform decisions, though any prematurity-related feeding decisions should be made in consultation with the infant’s medical team rather than based on litigation considerations.
You Might Also Like
- Zantac Ranitidine Cancer Contamination Mass Tort Litigation
- Tylenol Acetaminophen Autism ADHD Pregnancy Mass Tort Litigation
- Talcum Powder Ovarian Cancer Mass Tort Litigation
Open Settlements You Can Claim Now
Browse current class action settlements accepting claims — several require no proof of purchase: